The Pro Medicus (ASX:PME) share price has dropped 8% in 3 days. What's going on?

The dip in Pro Medicus shares is accompanied by a sector-wide sell-off.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in Pro Medicus Limited (ASX: PME) have had a poor run these past few days after falling off a high of $62.48 on 30 November.

There's been no market-sensitive information out of the Pro Medicus camp in this time. But that hasn't stopped investors selling off shares violently. The company opened Monday's session at $55.93 after pre-market trading.

A female health professional has a wide-eyed shocked expression on her face, even behind the face mask.

Image source: Getty Images

What's up with Pro Medicus shares?

Despite the recent weakness, shares in the health imaging IT provider were a standout performer in November. They closed out the month 17% in the green – well ahead of most healthcare majors.

However, the dip in Pro Medicus shares is accompanied by a sector-wide sell-off. This sell-off has been in situ since we rolled into December.

For instance, the S&P/ASX 200 Health Care Index (XHJ) has slipped 5% since the end of November, and shows no sign of slowing from the open today.

Concern around the Omicron COVID-19 variant and frothy share markets around the world has many investors taking risk off the table and seeking more defensive positions in safer assets, according to recent analysis from Goldman Sachs and JP Morgan.

Goldman has even lowered its 2022 US GDP forecasts from 4.2% to 3.8%, citing risks and potential impacts of the new strain, according to reporting from Bloomberg Intelligence.

This activity appears to have boded poorly for ASX health care shares, Pro Medicus included.

Although, the team at investment bank Citi reckons the pullback in the company's share price is warranted.

The firm rates Pro Medicus a sell at $45/share and reckons that investors could be overly optimistic in their growth projections for the company.

Citi notes the presence of many substitute products from Pro Medicus' competitors that could originate in future. This poses a threat to the company's profits and could compress its margins going forward, the broker says.

In the absence of any price-sensitive information out of the company's camp lately, it appears that weakness in the wider sector has spilled over into names like Pro Medicus as a negative catalyst to its share price.

Pro Medicus share price snapshot

In the past 12 months the Pro Medicus share price has climbed more than 90%. Pro Medicus shares have rallied 67% this year to date.

However, they have taken a backward step in the last month and are almost 7% in the red. The Pro Medicus share price has fallen 6.65% in just the last week of trading.

The author has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended SDI Limited and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »